Evidence map›Paper›PMID 38927466›Full record

ArticleBiomedicines2024

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) for Patients-3-Year Follow-Up of Patients with Chronic Kidney Disease.

Rumen Filev, Mila Lyubomirova, Boris Bogov, Krassimir Kalinov, Julieta Hristova, Dobrin Svinarov, Alexander Garev, Lionel Rostaing

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Long COVID and the kidney.Nature reviews. Nephrology · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rumen FilevDepartment of Nephrology, Internal Disease Clinic, University Hospital "Saint Anna", 1750 Sofia, Bulgaria.ORCID 0000-0003-1174-3128
Mila LyubomirovaDepartment of Nephrology, Internal Disease Clinic, University Hospital "Saint Anna", 1750 Sofia, Bulgaria.
Boris BogovDepartment of Nephrology, Internal Disease Clinic, University Hospital "Saint Anna", 1750 Sofia, Bulgaria.
Krassimir KalinovHead Biometrics Group, Comac-Medical Ltd., 1404 Sofia, Bulgaria.
Julieta HristovaFaculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.ORCID 0000-0001-9915-3282
Dobrin SvinarovFaculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.
Alexander GarevFaculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.
Lionel RostaingNephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, 38043 Grenoble, France.ORCID 0000-0002-5130-7286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-acute sequelae of SARS-CoV-2 (PASC) is a significant health concern, particularly for patients with chronic kidney disease (CKD). This study investigates the long-term outcomes of individuals with CKD who were infected with COVID-19, focusing on their health status over a three-year period post-infection. Data were collected from both CKD and non-CKD patients who survived SARS-CoV-2 infection and were followed for three years as part of a research study on the impact, prognosis, and consequences of COVID-19 infection in CKD patients. In this prospective cohort study, we analyzed clinical records, laboratory findings, and patient-reported outcomes assessed at intervals during follow-up. The results indicated no permanent changes in renal function in any of the groups analyzed, although patients without CKD exhibited faster recovery over time. Furthermore, we examined the effect of RAAS-blocker therapy over time, finding no influence on PASC symptoms or renal function recovery. Regarding PASC symptoms, most patients recovered within a short period, but some required prolonged follow-up and specialized post-recovery management. Following up with patients in the post-COVID-19 period is crucial, as there is still insufficient information and evidence regarding the long-term effects, particularly in relation to CKD.

Indexed as

CKDcomorbiditydyspnealong COVIDpainPASC

Identifiers

PMID38927466
PMCPMC11201278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.